대한뉴팜

A clinical trial conducted by the Institute of Veterinary Medicine at Gyeongsang National University on broiler farms in the Gyeongnam region, where coccidiosis outbreaks are common, found that administration of “Coccimyeol-S” significantly reduced mortality rates compared to the control group. The study also observed reductions in fecal diarrhea scores and intestinal lesion severity upon necropsy.

Coccidiosis affects all poultry species but occurs most severely in chickens and turkeys, causing major economic losses in the poultry industry. The protozoan parasites inhabit the intestinal tract, leading to diarrhea and enteritis, and in broiler farms, resulting in watery, loose, or bloody feces, reduced weight gain, and delayed shipping dates.

Through this clinical study, Daehan New Pharm confirmed that the group treated with “Coccimyeol-S” exhibited relatively higher weight gain compared to the untreated group (using 22-day-old broilers infected with Eimeria spp., tested by the Institute of Veterinary Medicine, Gyeongsang National University). “Coccimyeol-S” offers a shorter treatment period of just two days and an economical treatment cost of approximately 4–8 KRW per bird, compared to existing coccidiosis treatments. The withdrawal period is also short at only five days, allowing safe use even in cases of short shipping cycles. Moreover, the product shows minimal drug resistance and does not cause the side effects associated with traditional coccidiosis treatments, such as decreased water intake or weight gain. Daehan New Pharm has also newly launched “Lactoplanta,” an antibiotic alternative derived from fermented fish sauce.

[Published in Poultry Research, March 2012.]